Abstract:Host cellular receptors are key determinants of virus tropism and pathogenesis. Virus utilizes multiple receptors for attachment, entry, or specific host responses. However, other than ACE2, little is known about SARS-CoV-2 receptors. Furthermore, ACE2 cannot easily interpret the multi-organ tropisms of SARS-CoV-2 nor the clinical differences between SARS-CoV-2 and SARS-CoV. To identify host cell receptors involved in SARS-CoV-2 interactions, we performed genomic receptor profiling to screen almost all human membrane proteins, with SARS-CoV-2 capsid spike (S) protein as the target. Twelve receptors were identified, including ACE2. Most receptors bind at least two domains on S protein, the receptor-binding-domain (RBD) and the N-terminal-domain (NTD), suggesting both are critical for virus-host interaction. Ectopic expression of ASGR1 or KREMEN1 is sufficient to enable entry of SARS-CoV-2, but not SARS-CoV and MERS-CoV. Analyzing single-cell transcriptome profiles from COVID-19 patients revealed that virus susceptibility in airway epithelial ciliated and secretory cells and immune macrophages highly correlates with expression of ACE2, KREMEN1 and ASGR1 respectively, and ACE2/ASGR1/KREMEN1 (ASK) together displayed a much better correlation than any individual receptor. Based on modeling of systemic SARS-CoV-2 host interactions through S receptors, we revealed ASK correlation with SARS-CoV-2 multi-organ tropism and provided potential explanations for various COVID-19 symptoms. Our study identified a panel of SARS-CoV-2 receptors with diverse binding properties, biological functions, and clinical correlations or implications, including ASGR1 and KREMEN1 as the alternative entry receptors, providing insights into critical interactions of SARS-CoV-2 with host, as well as a useful resource and potential drug targets for COVID-19 investigation. ### Competing Interest Statement M.L., Z.L., Y.Z. H.G. and Y.X. are listed as inventors on a pending patent application for the newly identified S receptors described in this manuscript. The other authors declare no competing interests.

Control of SARS-CoV-2 infection by MT1-MMP-mediated shedding of ACE2

Sars-Cov-2 Infection Induces Emt-Like Molecular Changes, Including Zeb1-Mediated Repression Of The Viral Receptor Ace2, In Lung Cancer Models

Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system

Altered host protease determinants for SARS-CoV-2 Omicron

Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19

P21-activated kinase 1 (PAK1)-mediated cytoskeleton rearrangement promotes SARS-CoV-2 entry and ACE2 autophagic degradation

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury

ACE2 Shedding and the Role in COVID-19

Evaluating angiotensin-converting enzyme 2-mediated SARS-CoV-2 entry across species

Interaction network of SARS-CoV-2 with host receptome through spike protein

SARS-CoV-2 Receptor ACE2 is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Enriched in Specific Cell Subsets Across Tissues

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2)

Single‐cell RNA Analysis on ACE2 Expression Provides Insights into SARS‐CoV‐2 Potential Entry into the Bloodstream and Heart Injury

Manipulation of ACE2 expression in COVID-19

Recombinant Human ACE2: Potential Therapeutics of SARS-CoV-2 Infection and Its Complication

Characterization of the angiotensin-converting enzyme 2 (ACE2), the main receptor for the SARS-CoV-2 virus

Individual Variation of the SARS‐CoV‐2 Receptor ACE2 Gene Expression and Regulation

A Novel Unrecognized Mechanism for SARS-CoV-2 Immune-Mediated Pathology

Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart